Yahoo · Sep 23, 2026
RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says
RxSight (RXST) has upside potential if it executes salesforce expansion and utilization-growth initi
RX
NASDAQ · RXST
RxSight, Inc.
Healthcare · Medical - Devices
$4.76
Down-$0.11 (-2.31%)
Updated Oct 7, 2026, 1:58 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 539.04M
- P/E ratio
- -16.56
- Dividend yield
- 0.00%
- 52-week range
- $4.48 – $13.22
- Volume
- 483.76K
- Avg. volume
- 777.3K
Price performance · RXST
RXST price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
RXST closed at $4.76 after 20 trading sessions, down 26.20% for the selected period.
- Last close
- $4.76
- Period change
- -26.20%
- Period low
- $4.66
- Period high
- $6.45
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $4.70 | $4.805 | $4.62 | $4.76 | 483.76K |
| Oct 2, 2026 | $4.75 | $4.77 | $4.63 | $4.68 | 616.83K |
| Oct 1, 2026 | $4.88 | $4.89 | $4.74 | $4.75 | 508.92K |
| Sep 30, 2026 | $4.80 | $4.99 | $4.67 | $4.90 | 705.66K |
| Sep 29, 2026 | $4.67 | $4.78 | $4.62 | $4.77 | 810.93K |
| Sep 28, 2026 | $4.67 | $4.78 | $4.61 | $4.67 | 1.02M |
| Sep 25, 2026 | $4.72 | $4.78 | $4.63 | $4.66 | 1.12M |
| Sep 24, 2026 | $4.85 | $4.91 | $4.67 | $4.73 | 1.22M |
| Sep 23, 2026 | $4.90 | $4.9853 | $4.84 | $4.85 | 593.51K |
| Sep 22, 2026 | $5.05 | $5.16 | $4.90 | $4.93 | 849.6K |
| Sep 21, 2026 | $5.21 | $5.34 | $5.05 | $5.14 | 627.68K |
| Sep 18, 2026 | $5.25 | $5.3625 | $5.165 | $5.20 | 1.08M |
| Sep 17, 2026 | $5.58 | $5.58 | $5.17 | $5.32 | 1.01M |
| Sep 16, 2026 | $5.56 | $5.58 | $5.31 | $5.40 | 802.96K |
| Sep 15, 2026 | $6.05 | $6.05 | $5.60 | $5.62 | 679.27K |
| Sep 14, 2026 | $6.02 | $6.21 | $5.955 | $6.105 | 632.16K |
| Sep 11, 2026 | $6.00 | $6.025 | $5.78 | $6.02 | 450.65K |
| Sep 10, 2026 | $6.26 | $6.325 | $5.89 | $5.96 | 667.39K |
| Sep 9, 2026 | $6.41 | $6.655 | $6.265 | $6.33 | 1.21M |
| Sep 8, 2026 | $6.28 | $6.47 | $6.05 | $6.45 | 734.19K |
Latest RXST news
The latest Smart Investors Daily articles mentioning RXST.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RXST research
Overview
Company profile and research snapshot.
Company profile
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $10.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | Jefferies | Hold | — |
| Sep 22, 2026 | B of A Securities | Underperform | — |
| Aug 10, 2026 | Stifel | Hold | — |
| Aug 6, 2026 | UBS | Neutral | — |
| Jul 7, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 22, 2026
B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $5.5
B of A Securities analyst Craig Bijou maintains RxSight (NASDAQ:RXST) with a Underperform and lowers the price target from $6.5 to $5.5.
Yahoo · Aug 26, 2026
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company’s investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin
Yahoo · Aug 13, 2026
Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?
Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight’s proprietary light-adjustable technology, which allows eye surgeons to […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
